Research programme: non-nucleoside HCV NS5B polymerase inhibitors - Microbiotix Inc.
Alternative Names: HCV NS5B inhibitors - Microbiotix; MBX-701; SCH-900188Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Merck & Co
- Developer Microbiotix
- Class
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA
- 02 Jan 2013 Preclinical trials in Hepatitis C in USA (unspecified route)